U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory WHO Grade 1 Glioma

MedGen UID:
1791074
•Concept ID:
C5554633
•
Neoplastic Process
Synonym: Refractory WHO Grade I Glioma

Definition

WHO grade 1 glioma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory WHO Grade 1 Glioma

Professional guidelines

PubMed

Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.
Hajikarimloo B, Hasanzade A, Sabbagh Alvani M, Habibi MA
Neurosurg Rev 2024 Sep 27;47(1):692. doi: 10.1007/s10143-024-02889-w. PMID: 39327340

Recent clinical studies

Etiology

Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.
Reiss SN, Yerram P, Modelevsky L, Grommes C
J Immunother Cancer 2017 Dec 19;5(1):99. doi: 10.1186/s40425-017-0302-x. PMID: 29254497Free PMC Article
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S
J Clin Oncol 2012 Apr 20;30(12):1358-63. Epub 2012 Mar 5 doi: 10.1200/JCO.2011.34.5843. PMID: 22393086

Diagnosis

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.
Nelson MV, Kim A, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW
Oncologist 2024 Aug 5;29(8):723-e1093. doi: 10.1093/oncolo/oyae119. PMID: 38873934Free PMC Article
Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I
JAMA Oncol 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. PMID: 37883081Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824

Therapy

Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial.
Park JO, Feng YH, Su WC, Oh DY, Keam B, Shen L, Kim SW, Liu X, Liao H, Qing M, Zhang C, Qian J, Tang X, Li P, Triantos S, Sweiti H
BMC Cancer 2024 Aug 13;24(1):1006. doi: 10.1186/s12885-024-12584-0. PMID: 39138436Free PMC Article
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I
JAMA Oncol 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. PMID: 37883081Free PMC Article
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah NN
J Clin Oncol 2022 Mar 20;40(9):932-944. Epub 2021 Nov 12 doi: 10.1200/JCO.21.01405. PMID: 34767461Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824

Prognosis

Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I
JAMA Oncol 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. PMID: 37883081Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.
Chastagner P, Devictor B, Geoerger B, Aerts I, Leblond P, Frappaz D, Gentet JC, Bracard S, André N
Cancer Chemother Pharmacol 2015 Aug;76(2):425-32. Epub 2015 Jun 27 doi: 10.1007/s00280-015-2781-0. PMID: 26115930
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S
J Clin Oncol 2012 Apr 20;30(12):1358-63. Epub 2012 Mar 5 doi: 10.1200/JCO.2011.34.5843. PMID: 22393086

Clinical prediction guides

Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J
Cancer Med 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. PMID: 38850123Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S
J Clin Oncol 2012 Apr 20;30(12):1358-63. Epub 2012 Mar 5 doi: 10.1200/JCO.2011.34.5843. PMID: 22393086
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.
Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, Ananthakrishnan R, Boni JP, Berkenblit A, Spunt SL
Eur J Cancer 2012 Jan;48(2):253-62. Epub 2011 Oct 25 doi: 10.1016/j.ejca.2011.09.021. PMID: 22033322Free PMC Article

Recent systematic reviews

Application of bevacizumab in the management of meningiomas: a systematic review and meta-analysis.
Hajikarimloo B, Hasanzade A, Sabbagh Alvani M, Habibi MA
Neurosurg Rev 2024 Sep 27;47(1):692. doi: 10.1007/s10143-024-02889-w. PMID: 39327340

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...